Incidence of Thyroid Function Test Abnormalities in Patients Receiving Immune-Checkpoint Inhibitors for Cancer Treatment

Oncologist

Volumn 23, Issue 10, 2018, Pages 1236-1241

  Patel, Nisha Subhash ^a   Oury, Anais ^a   Daniels, Gregory A ^a   Bazhenova, Lyudmila ^a   Patel, Sandip Pravin ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Anti CTLA 4; Anti PD1; Ipilimumab; Nivolumab; Pembrolizumab; Thyroid

Indexed keywords

IPILIMUMAB; LEVOTHYROXINE; LIOTHYRONINE; NIVOLUMAB; PEMBROLIZUMAB; STEROID; THIAMAZOLE; THYROTROPIN; THYROXINE; PROGRAMMED DEATH 1 RECEPTOR;

ADOLESCENT; ADRENAL INSUFFICIENCY; ADULT; AGED; ANXIETY; ARTICLE; BODY WEIGHT GAIN; BODY WEIGHT LOSS; CANCER GROWTH; CENTRAL HYPOTHYROIDISM; CENTRAL HYPOTHYROIDISM,; COHORT ANALYSIS; COLITIS; CONSTIPATION; DIARRHEA; DISEASE COURSE; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FREE LIOTHYRONINE INDEX; FREE THYROXINE INDEX; HEART PALPITATION; HUMAN; HYPERTHYROIDISM; HYPOTHYROIDISM; INCIDENCE; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MYALGIA; NIGHT SWEAT; PATIENT; PRIMARY OVERT HYPERTHYROIDISM; RETROSPECTIVE STUDY; STEROID THERAPY; SUBCLINICAL HYPERTHYROIDISM; SUBCLINICAL HYPOTHYROIDISM; SUBSTITUTION THERAPY; THYROID DISEASE; THYROID FUNCTION TEST; THYROIDITIS; THYROTROPIN BLOOD LEVEL; COMPLICATION; MIDDLE AGED; NEOPLASM; PATHOLOGY; PROCEDURES; PSYCHOLOGY; QUALITY OF LIFE; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; NEOPLASMS; PROGRAMMED CELL DEATH 1 RECEPTOR; QUALITY OF LIFE; RETROSPECTIVE STUDIES; THYROID FUNCTION TESTS; YOUNG ADULT;

EID: 85047661921     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2017-0375     Document Type: Article

References (16)

1. Naidoo J, Page DB, Li BT et al. Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Ann Oncol 2015;26:2375–2391.
2. Corsello SM, Barnabei A, Marchetti P et al. Endocrine side effects induced by immune checkpoint inhibitors. J Clin Endocrinol Metab 2013;98:1361–1375.
3. Abdel-Wahab N, Shah M, Suarez-Almazor M. Adverse events associated with immune checkpoint blockade in patients with cancer: A systematic review of case reports. PLoS One 2016;11:e0160221.
4. Postow MA, Chesney J, Pavlick AC et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med 2015;372:2006–2017.
5. Larkin J, Chiarion-Sileni V, Gonzalez R et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 2015;373:23–34.
6. Wolchok J, Kluger H, Callahan M. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013;369:122–133.
7. Buchbinder E, Desai A. CTLA-4 and PD-1 pathways: Similarities, differences and implications of their inhibition. Am J Clin Oncol 2016;39:98–106.
8. Barroso-Sousa R, Barry W, Garrido-Castro A et al. Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: A systematic review and meta-analysis. JAMA Oncol Published online September 28, 2017. Doi:10.1001/jamaoncol.2017.3064.
9. Morganstein DL, Lai Z, Spain L et al. Thyroid abnormalities following the use of cytotoxic T-lymphocyte antigen-4 and programmed death receptor protein-1 inhibitors in the treatment of melanoma. Clin Endocrinol 1-7, 2017.
10. Rossi E, Sgambato A, De Chiara G et al. Thyroid-induced toxicity of check-point inhibitors immunotherapy in the treatment of advanced non-small cell lung cancer. J Endocrinol Diabetes 2016;3:1–10.
11. deFilette J, Jansen Y, Schreuer M et al. Incidence of thyroid-related adverse events in melanoma patients treated with pembrolizumab. J Clin Endocrinol Metab 2016;101:4431–4439.
12. Common Terminology Criteria for Adverse Events. 2010. https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf. Accessed Dec 16, 2016.
13. Lodish M, Stratakis C. Endocrine side effects of broad-acting kinase inhibitors. Endocr Relat Cancer 2010;17:233–244.
14. Joshi MN, Whitelaw BC, Palomar MT et al. Immune checkpoint inhibitor-related hypophysitis and endocrine dysfunction: Clinical review. Clin Endocrinol 2016;85:331–339.
15. Dillard T, Yedinak C, Alumkal J et al. Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis: Serious immune related adverse events across a spectrum of cancer subtypes. Pituitary 2010;13:29–38.
16. Iwama S, De Remigis A, Callahn MK et al. Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody. Sci Transl Med 2014;230–24515.